This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Sbi Pharmaceuticals Co., Ltd., Tokyo Institute of Technology. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 41 
1 out of 591 
Years Active: 2016
Title: Shigeharu Sato: Innovator in Antimalarial Drug Development
Introduction
Shigeharu Sato is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antimalarial drugs. His innovative work has the potential to impact global health positively.
Latest Patents
Sato holds a patent for an antimalarial drug comprising alaremycin or a derivative thereof as the active ingredient. The patent describes a preventive and/or therapeutic agent for malaria that includes 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or its derivatives. This invention aims to provide an effective treatment option for malaria, utilizing a compound that can be modified to enhance its efficacy.
Career Highlights
Throughout his career, Shigeharu Sato has worked with prestigious institutions, including the Tokyo Institute of Technology and Sbi Pharmaceuticals Co., Ltd. His experience in these organizations has allowed him to develop his expertise in pharmaceutical research and innovation.
Collaborations
Sato has collaborated with notable colleagues such as Masaaki Wachi and Tohru Tanaka. These partnerships have contributed to his research and development efforts in the pharmaceutical industry.
Conclusion
Shigeharu Sato's work in developing antimalarial drugs showcases his commitment to advancing medical science. His innovative approach and collaborations highlight the importance of teamwork in achieving breakthroughs in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile